Skip to main content
Clinical Trials/EUCTR2007-003186-40-SE
EUCTR2007-003186-40-SE
Active, not recruiting
Phase 1

Evaluation of antiplatelet effects of different dosages of aspirin in type 2 diabetic patients.

Karolinska Institute0 sites30 target enrollmentJuly 6, 2007

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with type 2 diabetes mellitus with an indication for aspirin treatment or already on aspirin treatment.
Sponsor
Karolinska Institute
Enrollment
30
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 6, 2007
End Date
October 6, 2010
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Karolinska Institute

Eligibility Criteria

Inclusion Criteria

  • 1\) Type 2 DM with micro or macro\-angiopathy.
  • 2\) Patients with need for aspirin treatment or already on aspirin treatment.
  • 2\) Age 50\-75 years
  • 3\) HbA1C 6\-9 %
  • 3\) Equal number of males and females
  • 4\) Antecubital forearm veins allowing technically good sampling for platelet studies.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\) Diet controlled DM.
  • 2\) Acute or chronic kidney disease
  • 3\) Acute or chronic liver disease
  • 4\) Need for treatment with anticoagulants, clopidogrel, NSAID’s, or thiazolidinediones.
  • 5\) Thrombocytopenia (platelet count \<150 x 109/L)
  • 6\) Anticipated need for alteration of concomitant drug therapy during the course of the study.
  • 7\) Enrolment in another clinical study.
  • 8\) Contraindication(s) to aspirin treatment.
  • 9\) A history of gastric or duodenal peptic ulcer disease.
  • 10\) Acute ischemic stroke, acute coronary syndrome or revascularization procedure in the past 6 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials